EVP & Chief Legal Officer Sells Over $10.6M in Jazz Pharmaceuticals Stock
JAZZ has more than doubled off its 52-week low of $95.49.
Summary
Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena Patil, sold over $10.6 million worth of company stock after exercising options, reducing her direct holdings.
Key Events · Ownership and Investor Activity · JAZZ
-
Significant Insider Sale
EVP & Chief Legal Officer Neena Patil sold 55,600 ordinary shares for a total of $10,650,482.29 in open market transactions on February 26, 2026.
-
Option Exercise Preceded Sale
The sale followed the exercise of options to acquire 51,000 shares for $6,488,700, indicating an 'exercise and sell' strategy.
-
Reduction in Direct Holdings
Post-transaction, Ms. Patil's direct holdings decreased to 83,946 shares.
-
Stock Trading Near 52-Week High
The sale occurred while Jazz Pharmaceuticals' stock is trading near its 52-week high of $198.00, potentially allowing the insider to lock in gains.
Analysis · JAZZ · Life Sciences
This Form 4 filing indicates a significant disposition of shares by a high-level executive. Neena Patil, EVP & Chief Legal Officer, sold over $10.6 million in ordinary shares following the exercise of options. While option exercises are often part of compensation plans, the subsequent large open market sale represents a substantial reduction in her direct ownership and could be interpreted as a lack of conviction or a move to diversify holdings, especially as the stock trades near its 52-week high. This transaction contributes to a broader pattern of insider distribution observed over the last 90 days.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAZZ was trading at $191.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.7B. The 52-week trading range was $95.49 to $198.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.